Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids.

导出 LinkOut

翻译打印收藏纠错

作者： Elias,Burri ^[1] ; Joanna,Mangana ^[2] ; Phil F,Cheng ^[1] ; Alia,Schneider ^[2] ; Achim,Weber ^[1] ; Reinhard,Dummer ^[2] ; Egle,Ramelyte ^[3]

作者单位： Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. ^[1] Medical Faculty, University of Zurich, Zurich, Switzerland. ^[2] Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. ^[3] Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland. ^[4] Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland egle.ramelyte@usz.ch. ^[5]

关键词 Immune Checkpoint Inhibitors Melanoma

主题词人类(Humans);男(雄)性(Male);女(雌)性(Female);回顾性研究(Retrospective Studies);中年人(Middle Aged);老年人(Aged);甾类(Steroids);肝炎(Hepatitis);成年人(Adult)

DOI 10.1136/jitc-2023-008074

PMID 38969522

发布时间 2024-07-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal for immunotherapy of cancer

2024年12卷7期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids.

Journal for immunotherapy of cancer

相似文献

Journal for immunotherapy of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids.

Journal for immunotherapy of cancer

相似文献

Journal for immunotherapy of cancer

相关期刊

检索历史清除